These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26984587)

  • 1. Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease.
    Park Y; Franchi F; Rollini F; Angiolillo DJ
    Circ J; 2016; 80(4):791-801. PubMed ID: 26984587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual antiplatelet therapy in patients with diabetes mellitus: special considerations.
    Capranzano P; Capodanno D
    Expert Rev Cardiovasc Ther; 2013 Mar; 11(3):307-17. PubMed ID: 23469911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes and antiplatelet therapy: from bench to bedside.
    Rivas Rios JR; Franchi F; Rollini F; Angiolillo DJ
    Cardiovasc Diagn Ther; 2018 Oct; 8(5):594-609. PubMed ID: 30498684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic specific aspects in antithrombotic therapy in patients with coronary artery disease.
    Farhan S; Höchtl T; Wojta J; Huber K
    Minerva Med; 2010 Aug; 101(4):239-53. PubMed ID: 21030936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction.
    Park Y; Franchi F; Rollini F; Angiolillo DJ
    Trends Cardiovasc Med; 2016 May; 26(4):321-34. PubMed ID: 26391344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike.
    Franchi F; Rollini F; Park Y; Angiolillo DJ
    Prog Cardiovasc Dis; 2015; 58(3):267-77. PubMed ID: 26277706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
    Ganetsky VS; Hadley DE; Thomas TF
    Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review.
    Khalil P; Kabbach G
    Curr Cardiol Rep; 2019 Jan; 21(1):5. PubMed ID: 30689068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.
    Cairns JA; McMurtry MS
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S60-70. PubMed ID: 23790600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Harrington RA; Becker RC; Ezekowitz M; Meade TW; O'Connor CM; Vorchheimer DA; Guyatt GH
    Chest; 2004 Sep; 126(3 Suppl):513S-548S. PubMed ID: 15383483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving long-term ACS management: is there a role for the new antiplatelets?
    Cohen M
    J Interv Cardiol; 2012 Oct; 25(5):425-32. PubMed ID: 22574644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oral anticoagulants in acute coronary syndrome.
    Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
    Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study.
    De Luca L; Leonardi S; Cavallini C; Lucci D; Musumeci G; Caporale R; Abrignani MG; Lupi A; Rakar S; Gulizia MM; Bovenzi FM; De Servi S;
    Eur Heart J Acute Cardiovasc Care; 2015 Oct; 4(5):441-52. PubMed ID: 25414322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet therapy for secondary prevention of coronary artery disease.
    Pilgrim T; Windecker S
    Heart; 2014 Nov; 100(22):1750-6. PubMed ID: 25037531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus.
    Capodanno D; Angiolillo DJ
    Circulation; 2020 Dec; 142(22):2172-2188. PubMed ID: 33253005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic therapy in the anticoagulated patient undergoing percutaneous coronary intervention with coronary stenting.
    Jhagroe DA; Janssen PW; Ten Berg JM
    Curr Opin Cardiol; 2015 Jul; 30(4):319-24. PubMed ID: 26049376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
    Packard KA; Campbell JA; Knezevich JT; Davis EM
    Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.
    Turpie AG
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):963-76. PubMed ID: 25017622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.